Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Korea Tries To Buffer Heavy Price Cuts With R&D Incentives, But Local And Global Pharma Up In Arms

This article was originally published in PharmAsia News

Executive Summary

TOKYO - South Korea's Ministry of Health and Welfare announced this week dual measures to drastically cut drug prices, while also committing to support Korea's innovation-focused companies through tax credits and preferential pricing
Advertisement

Related Content

South Korea Considers Restarting Market-based Actual Transaction Price System
Hanmi Receives First Korea FDA Approval For Generic Of BMS’ Baraclude
Korean Government Steps Up R&D Incentives For Domestic Companies And MNCs
GSK Sees Enduring Pricing Pressure Unlikely, Novo Projects Lower Growth In China, Lilly Bolsters Diabetes Presence In India: Emerging Markets Round Up (Part 1)
Korean Health Ministry's New Pricing System Draws Industry Criticism
President Lee Nominates Competition-friendly Bureaucrat As New Health Minister
Green Cross, LG Life Sciences Team Up To Sell Osteoarthritis Drug To Compete With Pfizer's Celebrex
Korea's Health Ministry To Unveil Steeper Price Cuts After Patent Loss; Generics Could Be The Big Loser
Korea's Health Ministry To Unveil Steeper Price Cuts After Patent Loss; Generics Could Be The Big Loser
Korea's Health Ministry Gets In The Act To Generate Korean Innovation For U.S. Markets
Advertisement
UsernamePublicRestriction

Register

SC078783

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel